Testing effectiveness (Phase 2)Ended earlyNCT03519178
What this trial is testing
PF-06873600 in People With Cancer
Who this might be right for
HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer
Pfizer 155